John Fluke - Cellcyte Genetics Insider

Cellcyte Genetics -- USA Stock  

USD 0.0001  0.00  0.00%

Chairman, Interm CEO and Chairman of Audit Committee

Mr. John M. Fluke, Jr., is Interim Principal Executive Officer and Director of CellCyte Genetics Corporationrationration. He is the Chairman of Fluke Capital Management, LP the Fluke investment and trust management company. He founded the company in 1976. Mr. Fluke graduated from the University of Washington in 1964, with a BS Degree in Electrical Engineering, and received his Master Degree in Electrical Engineering from Stanford University in 1966. Mr. Fluke joined his father firm, John Fluke Mfg. Co., in 1966 as a design engineer and held various engineering and general management positions. He was elected to the board of that company in 1976, appointed Chief Executive Officer in 1983 and Chairman from 1984. He served as CEO through 1987, Chairman through 1990 and a director of the Fluke Corporationration through July 1998 when the company was acquired by Danaher Corporationrationration. Mr. Fluke currently serves on the Boards of two emerging or reemerging companies Metron Systems, Inc. and MaestroSoft, Inc. . Over the last three decades many of Mr. Fluke governance positions with smaller companies have required direct and frequent interaction with management to balance the achievement of cash flow positive performance without deviating from governance practices. He also currently serves as a director of Tully Coffee Company and chairs its audit committee
Age: 71  Chairman Since 2007      
Fluke is a former director and chairman of the audit committee for PRIMUS International and American Seafoods Group where he served on the audit committee. He has also served on the boards and audit committees of Peoples National Bank and US Bank of Washington .

Management Efficiency

The company has return on total asset (ROA) of (415.29) % which means that it has lost $415.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (22.9) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

CellCyte Genetics Corporationration, a development stage biotechnology company, engages in the research and development of medical devices for cell expansion and maintenance in the United States. Cellcyte Genetics [CCYG] is traded as part of a regulated electronic over-the-counter service offered by the NASD.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Cellcyte Genetics to your portfolio

Top Management

Cellcyte Genetics Leadership Team
John Fluke, Chairman
Randy Lieber, Director, CPA
Douglas Cerretti, President, Ph.D

Stock Performance

Cellcyte Genetics Performance Indicators